Saurabh Saha Sells 55,000 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha sold 55,000 shares of the stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $15.93, for a total value of $876,150.00. Following the transaction, the chief executive officer now directly owns 331,017 shares in the company, valued at $5,273,100.81. The trade was a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Saurabh Saha also recently made the following trade(s):

• On Tuesday, January 21st, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $15.77, for a total value of $867,350.00.
• On Friday, December 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $17.44, for a total value of $959,200.00.
• On Friday, December 6th, Saurabh Saha sold 87,496 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $18.46, for a total value of $1,615,176.16.
• On Monday, November 25th, Saurabh Saha sold 299 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $18.23, for a total value of $5,450.77.
• On Friday, November 22nd, Saurabh Saha sold 1,671 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $18.24, for a total value of $30,479.04.

Centessa Pharmaceuticals Trading Down 0.7 %

Shares of Centessa Pharmaceuticals stock opened at $16.63 on Friday. The firm has a market cap of $2.19 billion, a price-to-earnings ratio of -10.87 and a beta of 1.53. The business has a 50-day moving average price of $16.71 and a 200-day moving average price of $15.83. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. Centessa Pharmaceuticals plc has a twelve month low of $7.75 and a twelve month high of $19.09.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CNTA. Price T Rowe Associates Inc. MD lifted its holdings in shares of Centessa Pharmaceuticals by 14.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,364,392 shares of the company’s stock valued at $89,854,000 after acquiring an additional 685,371 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Centessa Pharmaceuticals by 22.0% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,119,027 shares of the company’s stock valued at $85,744,000 after acquiring an additional 924,027 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Centessa Pharmaceuticals by 279.2% in the 4th quarter. Janus Henderson Group PLC now owns 4,909,487 shares of the company’s stock valued at $82,218,000 after acquiring an additional 3,614,623 shares during the last quarter. Farallon Capital Management LLC lifted its holdings in shares of Centessa Pharmaceuticals by 24.3% in the 4th quarter. Farallon Capital Management LLC now owns 3,498,709 shares of the company’s stock valued at $58,603,000 after acquiring an additional 684,391 shares during the last quarter. Finally, Point72 Asset Management L.P. lifted its holdings in shares of Centessa Pharmaceuticals by 26.2% in the 4th quarter. Point72 Asset Management L.P. now owns 3,426,599 shares of the company’s stock valued at $57,396,000 after acquiring an additional 710,936 shares during the last quarter. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on CNTA. TD Cowen began coverage on Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating for the company. Guggenheim reiterated a “buy” rating on shares of Centessa Pharmaceuticals in a research note on Monday, February 10th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Centessa Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $25.83.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.